<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01857752</url>
  </required_header>
  <id_info>
    <org_study_id>PEDSEYE0003</org_study_id>
    <secondary_id>22753</secondary_id>
    <nct_id>NCT01857752</nct_id>
  </id_info>
  <brief_title>Phase II Study Temozolomide for Retinoblastoma Metastatic to the Central Nervous System for Patients From Guatemala</brief_title>
  <official_title>Phase II Study Temozolomide for Retinoblastoma Metastatic to the Central Nervous System for Patients From Guatemala</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <brief_summary>
    <textblock>
      Primary Objectives:&#xD;
&#xD;
        1. To investigate the response rate (complete response plus partial response) of&#xD;
           temozolomide for 8 weeks (2 cycles), in patients with retinoblastoma metastatic to the&#xD;
           central nervous system (mass only) in two strata:&#xD;
&#xD;
             -  A. Initial diagnosis (mass)&#xD;
&#xD;
             -  B. At relapse (mass)&#xD;
&#xD;
        2. To determine hematologic toxicity: absolute neutrophil count (ANC), platelets and&#xD;
           hemoglobin count.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        1. To determine the response in other metastatic sites (non target) (orbit, bone marrow,&#xD;
           bone, lung, liver and others)&#xD;
&#xD;
        2. To determine the remission rate and time to relapse on temozolomide.&#xD;
&#xD;
        3. To document the response of leptomeningeal metastasis (cerebrospinal fluid) to&#xD;
           temozolomide&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    accrual&#xD;
  </why_stopped>
  <start_date type="Actual">March 2012</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>8 weeks</time_frame>
    <description>Response rate (complete response plus partial response) of temozolomide for 8 weeks (2 cycles), in patients with retinoblastoma metastatic to the central nervous system (mass only) in two strata:&#xD;
Initial diagnosis (mass)&#xD;
At relapse (mass)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the toxicity suffered during each cycle of temozolamide will be evaluated using the CTCAE v3.0</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Retinoblastoma</condition>
  <arm_group>
    <arm_group_label>temozolomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <arm_group_label>temozolomide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. This study must be evaluated and confirmed by the local ethics committees and&#xD;
             institutional review board of the participating institution, in accordance to the&#xD;
             declaration of Helsinki. Informed consent must be administered and the parent or&#xD;
             guardian must sign the document, authorized by the Ethics Committee and human subjects&#xD;
             (therapy can not start if the documents are not signed).&#xD;
&#xD;
          2. Patients less than 21 years of age with diagnosis of retinoblastoma with metastasis to&#xD;
             the CNS (central nervous system) must be confirmed by an ophthalmologist and/or a&#xD;
             pathologist; in conjunction with the pediatric oncologist.&#xD;
&#xD;
          3. Metastasis to the CNS is defined as a mass in the chiasm or other site in the CNS,&#xD;
             confirmed by MRI and/or&#xD;
&#xD;
             CT:&#xD;
&#xD;
               1. At diagnosis&#xD;
&#xD;
               2. At relapse after conventional therapy.&#xD;
&#xD;
             It is acceptable to have other sites of metastatic disease: lymphatic, bone, bone&#xD;
             marrow or others.&#xD;
&#xD;
          4. All sites of metastasis must be measured in 3 planes, in millimeters and described in&#xD;
             POND (Pediatric Oncology Network Database*)&#xD;
&#xD;
          5. Quality of life must be 3 by Lansky and 50% by Karnofksy&#xD;
&#xD;
          6. Hemogram: Hemoglobin of 7, ANC of 750, platelets of 75K.&#xD;
&#xD;
          7. Chemistry: direct bilirubin less than 3.0, indirect bilirubin less than 4.0, AST less&#xD;
             5x normal and ALT 5x normal, creatinine less than 1.5.&#xD;
&#xD;
          8. Treatment must start not more than 15 days from diagnosis of metastatic&#xD;
             retinoblastoma.&#xD;
&#xD;
          9. Every patient with relapse or progression into the CNS must be documented with CT scan&#xD;
             or MRI of the brain. Other sites of relapse may be evaluated, including bone marrow.&#xD;
&#xD;
         10. Patients who are newly diagnosed should have not received any other chemotherapeutic&#xD;
             therapy (with the exception of dexamethasone) 1 week before starting, or radiotherapy,&#xD;
             4 weeks before starting.&#xD;
&#xD;
         11. All patients to be included in this study must be presented to the principal&#xD;
             investigator using Horizon Live Web-conferencing through the Cure4Kids website.&#xD;
             Eligibility and target CNS sites will be determined, as well as non-target sites.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with metastatic to CNS with only CSF involvement are NOT ELIGIBLE.&#xD;
&#xD;
          2. Relapse patients should have NOT received chemotherapy for 4 weeks, and no patient&#xD;
             should have received nitroureas (melphalan, CCNU or mustard). No patient should have&#xD;
             received radiation therapy in the previous 42 days. These patients are NOT eligible.&#xD;
&#xD;
          3. Diagnosis of AIDS or HIV positive.&#xD;
&#xD;
          4. Patients with disease NOT in the CNS are NOT eligible&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandra Luna-Fineman</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Unidad Nacional de Oncologia Pediatrica</name>
      <address>
        <city>Guatemala</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Guatemala</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>March 25, 2013</study_first_submitted>
  <study_first_submitted_qc>May 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2013</study_first_posted>
  <last_update_submitted>January 26, 2017</last_update_submitted>
  <last_update_submitted_qc>January 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Retinoblastoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinoblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

